Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder

Innovative and safe approach to PTSD treatment will be evaluated in a randomized 190-patient clinical trial. PORTLAND, ORE. (PRWEB) DECEMBER 06, 2019 Nobilis Therapeutics, a clinical stage biotechnology company focused on development of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared[…]

Read more

Catapult X Announces New Awards Program, Science Educators’ Best of Show™, to Debut at the NSTA National Conference in Boston

Science Educators to Vote on Breakthrough Products and Services for Teaching and Learning BEAVERTON, ORE. (PRWEB) DECEMBER 06, 2019 Each year, the National Science Teaching Association (NSTA) brings together organizations from across the U.S. and abroad to share their products and services with educators attending the NSTA National Conference on Science[…]

Read more